2.Effect of levosimendan on B-type natriuretic peptide levels in patients with advanced heart failure: a meta-analysis.
Zhong-dong XU ; Wei-xiong HE ; Yi-fan ZHAO ; Shu-xuan XIA ; Bo HE ; Tao YANG ; De-xiong CAO ; Shu-ling PENG ; Jue LI ; Ming-hui CAO
Journal of Southern Medical University 2009;29(10):2027-2029
OBJECTIVETo conduct a meta-analysis of the effect of levosimendan on B-type natriuretic peptide (BNP) levels and evaluate the therapeutic effect of levosimendan on advanced heart failure.
METHODSA meta-analysis was performed on the selected data to analyze the effect of levosimendan on BNP levels.
RESULTSLevosimendan decreased BNP by a mean of 337.66 [95%CI (-296.30, -379.02)] pg/ml 24 h after the administration, and by 259.92 [95%CI (-195.76, -324.08)] pg/ml at 48 h, and by 123.09 [95%CI(-53.32,-195.86)] pg/ml at 1 week. Levosimendan resulted in improvements of the cardiac function by about 29%, 22%, and 10% at 24 h, 48 h and 1 week after the administration.
CONCLUSIONLevosimendan produces favorable effects on the cardiac functions and BNP levels.
Cardiotonic Agents ; therapeutic use ; Heart Failure ; blood ; drug therapy ; Humans ; Hydrazones ; therapeutic use ; Natriuretic Peptide, Brain ; blood ; Pyridazines ; therapeutic use
3.Testosterone therapy improves cardiac function of male rats with right heart failure.
Zong-Bin LI ; Jing WANG ; Ju-Xiang WANG ; Xun-Min CHEN ; Shi-Sen JIANG
National Journal of Andrology 2009;15(11):994-1000
OBJECTIVEClinical studies have shown decreased levels of sexual hormones, particularly testosterone deficiency, in men with chronic heart failure (CHF). The authors aimed to investigate the effect of testosterone on cardiac function and the possible mechanism of androgen protecting the heart in male rats.
METHODSForty-three male SD rats were randomly divided into 3 groups: right heart failure (RHF, n = 15), physiologic testosterone treatment (TT, n = 15) and control (n = 13). The RHF group was given intraperitoneal injection of monocrotaline at 60 mg/kg to make RHF models; the TT group was injected with testosterone at 5 mg/kg 3 days after monocrotaline administration; and the control group received equal volume of saline. The CD34+ cells in the peripheral blood of each rat were counted by flow cytometry. The levels of serum testosterone and tumor necrosis factor alpha (TNF-alpha) were measured by chemiluminescence immunoassay and enzyme linked immunosorbent assay, respectively. The hearts, lungs and livers of all the surviving rats were excised at 6 weeks for pathological and immunohistochemical examinations.
RESULTSThe level of serum testosterone was gradually decreased, while that of TNF-alpha obviously increased in the RHF group. After testosterone treatment, the TT group showed a remarkable improvement of cardiac performance and a significant decrease in the level of serum TNF-alpha as compared with the RHF group. Statistically significant differences were observed neither in the CD34+ cell count in the peripheral blood nor in the CD34+ expression of the myocardial cells between the TT and RHF groups.
CONCLUSIONPhysiological supplementation of testosterone can improve the cardiac function of RHF male rats, probably through its inhibition of TNF-alpha rather than by autologous mobilization of bone marrow stem cells.
Animals ; Heart Failure ; drug therapy ; metabolism ; Male ; Rats ; Rats, Sprague-Dawley ; Testosterone ; blood ; therapeutic use ; Tumor Necrosis Factor-alpha ; blood
4.Effects of recombinant human growth hormone on serum lipid in aged male patients with chronic heart failure.
Chinese Journal of Applied Physiology 2014;30(3):247-250
OBJECTIVETo investigate the effects of recombinant human growth hormone on serum lipid in aged male patients with chronic heart failure (CHF).
METHODSEighty seven patients with chronic heart failure(> or = 60 years old) were randomly divided into 2 groups: the CHF control group (n = 46) who received regular therapy and the CHF experimental group (n = 41) who received regular therapy and recombinant human growth hormone. The treatment would be continued for 3 months. Another group was normal control group (n = 10). The detection of serum growth hormone (GH), insulin-like growth factor (IGF-1), total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C) was carried out before and after treatment in the participants.
RESULTSBefore treatment, the levels of GH and IGF-1 were not significantly different among groups. After treatment, the levels of GH (0.71 +/- 0.34 vs 0.96 +/- 0.48) and IGF-1 (95.64 +/- 21.11 vs 111.64 +/- 23.14)in CHF experimental group were higher than those before the treatment. In CHF control group, the levels of GH(0.81 +/- 0.32 vs 0.79 +/- 0.29) and IGF-1 (97.82 +/- 19.74 vs 99.65 +/- 20.11) had no significant change after the treatment. After treatment, the levels of GH (0.96 +/- 0.48 vs 0.79 +/- 0.29) and IGF-1 (111.64 +/- 23.14 vs 99.65 +/- 20.11) in CHF experimental group were higher compared with that of CHF control group. Before treatment, the serum levels of LDL-C, HDL-C, TC and TG had no significant difference among groups. After treatment,the levels of LDL-C (2.11 +/- 0.82 vs 1.76 +/- 0.51) and TC (3.78 +/- 1.34 vs 3.21 +/- 1.17) in CHF experimental group were lower than those before the treatment. However, the levels of HDL-C (1.10 +/- 0.31 vs 0.99 +/- 0.28)and TG (1. 89 +/- 1.07 vs 1.66 +/- 0.95) had no significant change after the treatment compared with before treatment. In CHF control group, the serum lipid levels had no significant change after the treatment.
CONCLUSIONAs the treatment of rhGH for aged male patients with chronic heart failure, GH influences lipid metabolism, which reduces the level of LDL-C, TC. However GH has no effects on the serum HDL-C and TG level. With the treatment of rhGH for long-term, lipid metabolism should be paid attention,and the treatment for blood lipid reduction should be adjusted in time.
Aged ; Chronic Disease ; Heart Failure ; blood ; therapy ; Human Growth Hormone ; pharmacology ; Humans ; Lipids ; blood ; Male ; Recombinant Proteins ; pharmacology
5.A Case of Successfully Treated Severe Heart Failure due to Cyclophosphamide Induced Cardiomyopathy.
Jung Min PARK ; Seung Min HAHN ; Jung Woo HAN ; Chuhl Joo LYU
Clinical Pediatric Hematology-Oncology 2018;25(1):71-75
Cyclophosphamide-induced cardiotoxicity is an uncommon complication especially in patients who have never undergone mediastinal irradiation or cardiotoxic chemotherapy and do not have underlying cardiac diseases. Here, we describe the case of a 19-year-old female with chronic myeloid leukemia. She was previously treated with oral tyrosine kinase inhibitors and developed cardiomyopathy after receiving infusion of 60 mg/kg intravenous cyclophosphamide for two days with a conditioning regimen for allogenic hematopoietic stem cell transplantation. Severe thickening of the left ventricle and reduced ejection fraction without triggering agents were characteristic for cyclophosphamide-induced cardiomyopathy. Her NT-pro BNP and troponin T concentrations surged to >70,000 pg/mL (0=130 pg/mL) and 2,031 pg/mL (0-14 pg/mL), respectively, during the course of the therapy and multiple organ failure seemed imminent evidenced by unresponsive decline in blood pressure. However, with close monitoring and persistent conservative management which consisted of intravenous hydration, continuous hemodialysis, and mechanical ventilation, her condition recovered.
Blood Pressure
;
Cardiomyopathies*
;
Cardiotoxicity
;
Cyclophosphamide*
;
Drug Therapy
;
Female
;
Heart Diseases
;
Heart Failure*
;
Heart Ventricles
;
Heart*
;
Hematopoietic Stem Cell Transplantation
;
Humans
;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
;
Multiple Organ Failure
;
Protein-Tyrosine Kinases
;
Renal Dialysis
;
Respiration, Artificial
;
Troponin T
;
Young Adult
6.Additive Benefits of Twice Forest Bathing Trips in Elderly Patients with Chronic Heart Failure.
Gen Xiang MAO ; Yong Bao CAO ; Yan YANG ; Zhuo Mei CHEN ; Jian Hua DONG ; Sha Sha CHEN ; Qing WU ; Xiao Ling LYU ; Bing Bing JIA ; Jing YAN ; Guo Fu WANG
Biomedical and Environmental Sciences 2018;31(2):159-162
Chronic heart failure (CHF), a clinical syndrome resulting from the consequences of various cardiovascular diseases (CVDs), is increasingly becoming a global cause of morbidity and mortality. We had earlier demonstrated that a 4-day forest bathing trip can provide an adjunctive therapeutic influence on patients with CHF. To further investigate the duration of the impact and the optimal frequency of forest bathing trips in patients with CHF, we recruited those subjects who had experienced the first forest bathing trip again after 4 weeks and randomly categorized them into two groups, namely, the urban control group (city) and the forest bathing group (forest). After a second 4-day forest bathing trip, we observed a steady decline in the brain natriuretic peptide levels, a biomarker of heart failure, and an attenuated inflammatory response as well as oxidative stress. Thus, this exploratory study demonstrated the additive benefits of twice forest bathing trips in elderly patients with CHF, which could further pave the way for analyzing the effects of such interventions in CVDs.
Aged
;
Chronic Disease
;
Complementary Therapies
;
methods
;
Forests
;
Heart Failure
;
blood
;
drug therapy
;
therapy
;
Heart Function Tests
;
Humans
;
Interleukin-6
;
blood
;
Natriuretic Peptide, Brain
;
blood
;
Oxidative Stress
;
Recreation
;
Treatment Outcome
;
Tumor Necrosis Factor-alpha
;
blood
7.Decrease of plasma N-terminal pro beta-type natriuretic peptide as a predictor of clinical improvement after cardiac resynchronization therapy for heart failure.
Li-Gang DING ; Wei HUA ; Shu ZHANG ; Jian-Min CHU ; Ke-Ping CHEN ; Yang WANG ; Fang-Zheng WANG ; Xin CHEN
Chinese Medical Journal 2009;122(6):617-621
BACKGROUNDN-terminal pro beta-type natriuretic peptide (NT pro BNP) has been shown to predict the prognosis and could guide the treatment of heart failure. We aimed to investigate the values of NT pro BNP in predicting the clinical response to cardiac resynchronization therapy (CRT).
METHODSA total of 44 patients with chronic heart failure (34 male and 10 female, mean age of (58 +/- 13) years, New York Heart Association (NYHA) class 3.3 +/- 0.5, QRS duration (150 +/- 14) milliseconds) who underwent successful implantation of a CRT system were enrolled in this study. Pharmacotherapy remained stable during the first 3 months of follow-up. Plasma levels of NT pro BNP were evaluated before and 3 months after implantation. Clinical, echocardiographic and exercise parameters were monitored at each clinical visit after CRT implantation. Receiver operating characteristic analysis and a paired t test were performed to analyze the data.
RESULTSAfter a mean of (16.3 +/- 5.5) months of follow-up, 11 nonresponders were identified. CRT resulted in a significant reduction in NT pro BNP ((1.70 +/- 1.28) vs (1.07 +/- 0.88) pmol/ml, P < 0.001) in responders. Percentage change in NT pro BNP level (DeltaBNP%) was a statistically significant predictor of long term clinical improvement at 3 months of follow-up.
CONCLUSIONSDeltaBNP% from baseline to 3 months of follow-up is a predictor of long term response to CRT. NT pro BNP may be a simple method for monitoring the effects of CRT.
Aged ; Cardiac Pacing, Artificial ; methods ; Female ; Heart Failure ; blood ; therapy ; Humans ; Male ; Middle Aged ; Natriuretic Peptide, Brain ; blood ; Peptide Fragments ; blood ; Prognosis ; Time Factors
8.Effect of blood activating water relieving method on heart functions and serum levels of NT-proBNP in patients with heart failure with normal ejection fraction.
Guo-Liang ZOU ; Wei-Li ZHONG ; Yan-Bo SUI ; Juan JIN ; Li LIU
Chinese Journal of Integrated Traditional and Western Medicine 2014;34(2):146-148
OBJECTIVETo study the effect of blood activating water relieving method (BAWRM) on heart functions and serum levels of NT-proBNP in patients with heart failure with normal ejection fraction (HFNEF).
METHODSSixty-four HFNEF patients were admitted to our hospital during January 2011 to June 2012. They were randomly assigned to the treatment group (32 cases) and the control group (32 cases). Patients in the control group received routine Western medical treatment, while those in the treatment group additionally took Chinese medical recipes for activating blood circulation and relieving water retention. Changes of Chinese medical syndromes, E/E', serum NT-proBNP contents were observed between the two groups.
RESULTSCompared with before treatment, their Chinese medical syndromes and E/E' were significantly improved, and serum NT-proBNP contents decreased in the two groups (P < 0.05). Compared with the control group, Chinese medical syndromes, E/E', serum NT-proBNP contents obviously decreased in the treatment group, showing statistical difference (P < 0.05).
CONCLUSIONBAWRM was an effective way to improve the diastolic function of HFNEF patients and lower the serum level of NT-proBNP with confirmative efficacy.
Aged ; Female ; Heart Failure ; blood ; drug therapy ; physiopathology ; Humans ; Male ; Medicine, Chinese Traditional ; methods ; Middle Aged ; Natriuretic Peptide, Brain ; blood ; Peptide Fragments ; blood ; Stroke Volume
9.Effects of phosphocreatine on plasma brain natriuretic peptide level in elderly patients with chronic congestive heart failure.
Xiao-hong DU ; Fei-yu LIANG ; Xiao-wei ZHAO
Journal of Southern Medical University 2009;29(1):154-159
OBJECTIVETo investigate the therapeutic effects of phosphocreatine in elderly patients with chronic congestive heart failure (CHF) and its effects on plasma brain natriuretic peptide (BNP).
METHODSForty elderly patients with chronic CHF were randomly divided into two groups to receive basic treatment (control group) and additional phosphocreatine treatment (treatment group) with a treatment course of 8 weeks. The patients were evaluated for improvement in New York Heart Association (NYHA) functional class, symptoms, left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter (LVESD), and left ventricular ejection fraction (LVEF) and the levels of BNP before and after treatment.
RESULTSAfter 8 weeks of treatment, the overall efficacy rate was significantly higher in treatment group than in the control group, and LVESD, LVEDD, LVEF and BNP level of the treatment group were significantly lowered in comparison with those of the control group (P<0.05).
CONCLUSIONPhosphocreatine in addition to the basic treatment can reduce the BNP level and improve the cardiac systolic and diastolic function in elderly patients with chronic CHF.
Aged ; Aged, 80 and over ; Cardiotonic Agents ; therapeutic use ; Female ; Heart Failure ; blood ; drug therapy ; Humans ; Male ; Natriuretic Peptide, Brain ; blood ; Phosphocreatine ; therapeutic use ; Ventricular Dysfunction, Left ; physiopathology
10.Brain natriuretic peptide and optimal management of heart failure.
Journal of Zhejiang University. Science. B 2005;6(9):877-884
Aside from the important role of brain natriuretic peptide (BNP) in diagnosis, and differential diagnosis of heart failure, this biological peptide has proved to be an independent surrogate marker of rehospitalization and death of the fatal disease. Several randomized clinical trials demonstrated that drugs such as beta blocker, angiotensin converting enzyme inhibitor, spironolactone and amiodarone have beneficial effects in decreasing circulating BNP level during the management of chronic heart failure. The optimization of clinical decision-making appeals for a representative surrogate marker for heart failure prognosis. The serial point-of-care assessments of BNP concentration provide a therapeutic goal of clinical multi-therapy and an objective guidance for optimal treatment of heart failure. Nevertheless new questions and problems in this area remain to be clarified. On the basis of current research advances, this article gives an overview of BNP peptide and its property and role in the management of heart failure.
Algorithms
;
Cardiotonic Agents
;
therapeutic use
;
Decision Making, Computer-Assisted
;
Heart Failure
;
blood
;
classification
;
etiology
;
therapy
;
Humans
;
Natriuretic Peptide, Brain
;
blood
;
physiology